Costco Wholesale (NASDAQ:COST) is venturing into the Medicare arena, teaming up with nonprofit SCAN Group to offer Medicare Advantage and supplemental insurance plans in three U.S. markets. The proposed products, pending regulatory approval, would target approximately 5 million Medicare-eligible individuals—a pool that represents about 6% of Costco's 82.9 million paid memberships. While this marks a significant potential market, both companies have remained tight-lipped about expected enrollment figures, commission structures, or launch timelines.
The pilot's addressable market is a useful scale indicator but should not be interpreted as a forecast of sign-ups. Federal regulations prohibit Costco from bundling insurance with its warehouse membership, so the initiative is best viewed as ancillary-service optionality until concrete conversion data emerges. Investors should temper expectations until management provides specifics on how the program will drive revenue or member engagement.
Strategic Fit and Member Value
Costco's pharmacy website already features SCAN Medicare coverage, and the proposed plans may include prescription drug, over-the-counter, vision, and audiology benefits—services that align with Costco's existing healthcare footprint. Chief Executive Ron Vachris stated the agreement should “create value for our members,” setting a clear hurdle: a product that improves member retention could prove more valuable than near-term commission income.
The move comes as Costco's core business remains robust. In the fiscal third quarter, membership fees rose 10.7% to $1.373 billion. Paid memberships reached 82.9 million, with a U.S.-Canada renewal rate of 92.2%. July net sales climbed 10.7% to $23.12 billion, while digitally enabled comparable sales surged 17.7%—nearly double the companywide rate.
Market Reaction and Stock Performance
Costco shares ended Friday at $947.74, up 1.52%, after a volatile week. The stock finished 1.39% below its August 14 close, and Friday's trading volume ran about 29% above the prior four-session average. The weekly fluctuations reflect investor uncertainty around the Medicare pilot and valuation concerns, with the stock trading at roughly 47-48 times forward earnings.
Wall Street remains broadly positive, though price targets vary widely. The average target among 39 analysts is $1,077, implying 13.7% upside. Targets range from $740 to $1,315. Recent calls highlight the valuation debate: Evercore carries a $1,100 target, Goldman Sachs lists $1,159, while Roth MKM's $781 target reflects a more cautious downside case.
Key Metrics and Forward Outlook
In the latest quarter, Costco reported diluted EPS of $4.93, up 15.2% year-over-year. July's comparable sales rose 8.9% across all markets, with digitally enabled comps up 17.7%. These figures underscore the retailer's operational strength, even as the market weighs the potential impact of the Medicare initiative.
Investors will be watching for more details on the pilot in the coming weeks. Management's ability to quantify the opportunity—without overpromising—will be critical. Any disclosure on commissions, participating states, or launch timing would help analysts model the financial impact.
Risks and Considerations
Potential risks include regulatory approval delays, weak plan uptake, or added operating costs that could erase the pilot's benefits. Additionally, Costco's premium valuation leaves little room for slower core sales growth. If the Medicare experiment fails to gain traction, the stock could face downward pressure despite its strong fundamentals.
As the healthcare landscape evolves, Costco's move into Medicare could either become a meaningful revenue stream or remain a niche experiment. For now, the market's cautious optimism reflects the uncertainty. The coming quarters will reveal whether this pilot can translate member trust into a successful insurance venture.
